Follow us on Twitter
This page is updated frequently with new Leukemia-related patents. Subscribe to the Leukemia RSS feed to automatically get the update: related Leukemia RSS feeds.
Subscribe to updates on this page: Leukemia RSS
|| List of recent Leukemia-related patents
| Treatment of acute lymphoblastic leukemia|
The present invention relates to a method for the treatment, amelioration or elimination of acute lymphoblastic leukemia (all), the method comprising the administration of a pharmaceutical composition comprising a cd19xcd3 bispecific single chain antibody construct to an adult patient in the need thereof.. .
|Use of artemisine derivatives and pharmaceutical salts thereof|
The invention demonstrates the application of an artemisinin derivative and its pharmaceutical salt. The artemisinin derivatives diarteether amine and its pharmaceutical salt inhibit the proliferation of leukemic cells, block the cell cycle of leukemic cells and induce the apoptosis of leukemic cells.
|Methods and compositions based on diphtheria toxin-interleukin-3 conjugates|
The present invention provides methods for inhibiting interleukin-3 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using a diphtheria toxin-human interleukin-3 conjugate (dt-il3) that is toxic to cells expressing the interleukin-3 receptor. In preferred embodiments, the dt-il3 conjugate is a fusion protein comprising amino acids 1-388 of diphtheria toxin fused via a peptide linker to full-length, human interleukin-3.
|Method of using tea polyphenols for prevention and treatment of malignant tumors in a hematopoietic system|
Tea polyphenols are used to prevent or treat tumors such as leukemia and myeloma, malignant tumors in a hematopoietic system. The tea polyphenols are tea extracts comprising egcg, egc, and ecg, or tegreen97®, a green tea capsule of pharmanex, inc..
|Use of a new histamine h4 agonist for the treatment of acute leukemia|
A method of treating leukemia by administering an h4 agonist of histamine, 7-amino-4,5,6-triethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl) phthalide (tritoqualine), to a subject is provided.. .
|Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis|
The invention describes compositions and methods of use for 2,5-dihydroxybenzene sulfonic acid compounds and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy; (e) treating rosacea; and (f) treating psoriasis by administration of a composition comprising at least one 2,5-dihydroxybenzene sulfonic acid compound or a pharmaceutically acceptable salt thereof, and, optionally at least one therapeutic agent.
|Treatment of blood cancer|
Hypoxia activated prodrugs, such as, e.g., th-281, th-302, and th-308, are useful for the treatment of various blood cancers, such as acute leukemias, chronic leukemias, mds, mf, and multiple myeloma.. .
|Muc18 targeting peptides|
Provided are muc18 targeting peptides which may be used, e.g., to therapeutically target b-1 lymphocytes to reduce the influence of these cells on the metastatic potential of melanoma cells and/or to target cancerous cells, including certain melanoma and leukemia cells. Muc18 targeting peptides may be comprised in fusion constructs, imaging constructs, and/or therapeutic constructs such as fusion constructs which may be used for diagnosing or treating a cancer..
|Methods for detecting risk of myelodysplastic syndrome by genotypic analysis|
The present invention provides methods for detecting the risk of developing leukemia using genotyping analysis, for example of a snp located in the promoter region of epo. The present invention also provides kits and nucleic acids for the detection of the risk genotype..
|Use of pegylated recombinant human arginase for treatment of leukemia|
The present invention provides a method for treatment of leukemia comprising administration of arginase to a subject in need thereof. In one embodiment, the leukemia is lymphocytic or myeloid.
|Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases|
Disclosed are compositions and methods comprising combinations of anti-cd74 antibodies with a therapeutic agent that is attached to the anti-cd74 antibody or separately administered. Preferably, the therapeutic agent is an antibody that binds to an antigen different from cd74, such as cd19, cd20, cd21, cd22, cd23, cd37, cd40, cd40l, cd52, cd80, il-6, cxcr4 or hla-dr.
|Therapeutic agent for pulmonary small cell carcinoma|
The invention aims to clarify further functions of a t-cell leukemia translocation-associated gene (tcta) protein-derived peptide and provide a novel application of the peptide. The invention provides a therapeutic agent for pulmonary small cell carcinoma or a cell growth inhibitor of pulmonary small cell carcinoma, comprising any peptide described in seq id nos 1 to 5..
|Cell culture model for acquired chemoresistance of chronic myelogenous leukemia and related methods for identifying agents to overcome resistance|
A method of generating a chronic myelogenic leukemia (cml) acquired chemoresistant culture model is provided. Such a method may comprise providing a naïve blast crisis cml cell line; administering/contacting the cell line with a mutation-inducing dose of imatinib; maintaining a culture of the treated cell line for a period of time until the treated cell line relapses and repopulates the culture; and determining the repopulated cell culture is a cml acquired chemoresistant cell line by detecting a bcr-abl mutation, wherein the acquired chemoresistance is achieved by a bcr-abl mutation..
|Wt1 mutations for prognosis of myeloproliferative disorders|
The invention provides methods for determining the prognosis of a patient diagnosed with a leukemia, including b-cell chronic lymphocytic leukemia, by measuring mutations of the wt1 gene in a biological sample. The invention also relates to the diagnosis of leukemia, including b-cell chronic lymphocytic leukemia..
|Use of jam-a in diagnosing and treating leukemia|
Methods, compositions, and kits are provided for the use of jam-a in diagnosing and treating leukemia. These methods, compositions, and kits find many uses, for example in diagnosing an individual with a leukemia, classifying a leukemia, providing a prognosis to an individual with a leukemia, treating an individual with a leukemia, screening candidate agents for the ability to treat a leukemia, and in basic research to better understand the molecular and cellular basis of leukemia..
|Acute leukemia and lymphoblastic lymphoma-specific cd43 epitope and use thereof|
The present invention relates to a cd43 epitope expressed on human acute leukemia and lymphoblastic lymphoma cells and its use. More particularly, the present invention relates to a cd43 epitope expressed on human acute leukemia, lymphoblastic lymphoma cells, but not on mature hematopoietic cells, hematopoietic stem cells and non-hematopoietic cells, and to its diagnostic and therapeutic application on acute leukemia and lymphoblastic lymphoma..
|Inhibitors of c-fms kinase|
Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
|Treatment of diseases by epigenetic regulation|
The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (bet) proteins. The disclosed compositions and methods can be used for treatment and prevention of cancer, including nut midline carcinoma, burkitt's lymphoma, acute myelogenous leukemia, and multiple myeloma; autoimmune or inflammatory diseases or conditions, and sepsis..
|Treatment of diseases by epigenetic regulation|
The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (bet) proteins. The disclosed compositions and methods can be used for treatment and prevention of cancer as well as sepsis, including nut midline carcinoma, burkitt's lymphoma, acute myelogenous leukemia, and multiple myeloma..
|Composition for reprogramming somatic cells to generate induced pluripotent stem cells, comprising oct4 in combination with bmi1 or its upstream regulator, and method for generating induced pluripotent stem cells using the same|
Disclosed is a composition for reprogramming somatic cells to generate embryonic stem cell-like cells, comprising: a) a bmi1 (b cell-specific moloney murine leukemia virus integration site 1) protein or a nucleic acid molecule coding for bmi1; and b) an oct4 protein or a nucleic acid molecule coding for oct4. Also, a method is provided for reprogramming somatic cells to generate embryonic stem cell-like cells using the composition.
|Gene signatures for prediction of therapy-related myelodysplasia and methods for identification of patients at risk for development of the same|
In one embodiment, a gene expression signature for predicting risk of developing therapy-related myelodysplasia or acute myeloid leukemia (t-mds/aml) after autologous hematopoietic cell transplantation (ahct) is provided. In another embodiment, a method for predicting a risk for development of t-mds/aml after ahct is provided.
Popular terms: [SEARCH]
Leukemia topics: Myelogenous, Myelogenous Leukemia, Proliferative, Autoimmune, Stem Cells, Breast Cancer, Rheumatoid Arthritis, Myeloid Leukemia, Acute Myelogenous Leukemia, Lymphocytic, Chronic Lymphocytic Leukemia, Lymphocytic Leukemia, Epigenetic, Multiple Myeloma, Polyphenol
Follow us on Twitter
This listing is a sample listing of patents related to Leukemia for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Leukemia with additional patents listed. Browse our RSS directory or Search for other possible listings.